Study of Cabergoline in Treatment of Corticotroph Pituitary Tumor

PHASE3CompletedINTERVENTIONAL
Timeline

Start Date

November 30, 2007

Conditions
Cushing's DiseaseCorticotroph Adenoma
Interventions
DRUG

Cabergoline

Dose 1 mg/week in divided doses, increased by 1 mg/week every month, to the maximum of 5 mg/week. If response is seen than the dose at which response is seen is continued until the end of the study.

Trial Locations (1)

4000012

Seth GSMC & KEM hospital, Mumbai

All Listed Sponsors
lead

Seth Gordhandas Sunderdas Medical College

OTHER

NCT00889525 - Study of Cabergoline in Treatment of Corticotroph Pituitary Tumor | Biotech Hunter | Biotech Hunter